keyword
MENU ▼
Read by QxMD icon Read
search

infusion chemotherapy

keyword
https://read.qxmd.com/read/30761413/the-accumulation-and-effects-of-liposomal-doxorubicin-in-tissues-treated-by-radiofrequency-ablation-and-irreversible-electroporation-in-liver-in-vivo-experimental-study-on-porcine-models
#1
Tomáš Andrašina, Josef Jaroš, Tomáš Jůza, Tomáš Rohan, Dalibor Červinka, Michal Crha, Vlastimil Válek, Nahum S Goldberg
PURPOSE: To compare the accumulation and effect of liposomal doxorubicin in liver tissue treated by radiofrequency ablation (RFA) and irreversible electroporation (IRE) in in vivo porcine models. MATERIALS AND METHODS: Sixteen RFA and 16 IRE procedures were performed in healthy liver of two groups of three pigs. Multi-tined RFA parameters included: 100 W, target temperature 105°C for 7 min. 100 IRE pulses were delivered using two monopolar electrodes at 2250 V, 1 Hz, for 100 µsec...
February 13, 2019: Cardiovascular and Interventional Radiology
https://read.qxmd.com/read/30753911/simple-surface-emg-recording-as-a-noninvasive-screening-method-for-the-detection-of-acute-oxaliplatin-induced-neurotoxicity-a-feasibility-pilot-study
#2
Sandra A S van den Heuvel, Jonne Doorduin, Monique A Steegers, Ewald M Bronkhorst, Sandra A Radema, Kris C Vissers, Selina E van der Wal, Nens van Alfen
OBJECTIVES: Oxaliplatin-induced neurotoxicity can be a dose-limiting side effect to effective chemotherapy. Acute hyperexcitability causes cold-evoked sensory and motor symptoms, which resemble neuromyotonia. An accessible and non-invasive technique for early detection could help select patients for potential treatments. We assessed the use of a simple surface electromyography (sEMG) in patients directly after oxaliplatin infusion. METHODS: In patients with colorectal cancer, acute neurotoxicity was evaluated by means of a physical examination, a questionnaire, and sEMG directly after the second and fourth cycle of oxaliplatin...
February 9, 2019: Neuroscience Letters
https://read.qxmd.com/read/30747243/phase-ii-clinical-trial-of-adoptive-cell-therapy-for-patients-with-metastatic-melanoma-with-autologous-tumor-infiltrating-lymphocytes-and-low-dose-interleukin-2
#3
Linh T Nguyen, Samuel D Saibil, Valentin Sotov, Michael X Le, Leila Khoja, Danny Ghazarian, Luisa Bonilla, Habeeb Majeed, David Hogg, Anthony M Joshua, Michael Crump, Norman Franke, Anna Spreafico, Aaron Hansen, Ayman Al-Habeeb, Wey Leong, Alexandra Easson, Michael Reedijk, David P Goldstein, David McCready, Kazuhiro Yasufuku, Thomas Waddell, Marcelo Cypel, Andrew Pierre, Bianzheng Zhang, Sarah Boross-Harmer, Jane Cipollone, Megan Nelles, Elizabeth Scheid, Michael Fyrsta, Charlotte S Lo, Jessica Nie, Jennifer Y Yam, Pei Hua Yen, Diana Gray, Vinicius Motta, Alisha R Elford, Stephanie DeLuca, Lisa Wang, Stephanie Effendi, Ragitha Ellenchery, Naoto Hirano, Pamela S Ohashi, Marcus O Butler
Adoptive cell therapy using autologous tumor-infiltrating lymphocytes (TIL) has shown significant clinical benefit, but is limited by toxicities due to a requirement for post-infusion interleukin-2 (IL-2), for which high dose is standard. To assess a modified TIL protocol using lower dose IL-2, we performed a single institution phase II protocol in unresectable, metastatic melanoma. The primary endpoint was response rate. Secondary endpoints were safety and assessment of immune correlates following TIL infusion...
February 11, 2019: Cancer Immunology, Immunotherapy: CII
https://read.qxmd.com/read/30736852/allogenic-v%C3%AE-9v%C3%AE-2-t-cell-as-new-potential-immunotherapy-drug-for-solid-tumor-a-case-study-for-cholangiocarcinoma
#4
Mohammed Alnaggar, Yan Xu, Jingxia Li, Junyi He, Jibing Chen, Man Li, Qingling Wu, Li Lin, Yingqing Liang, Xiaohua Wang, Jiawei Li, Yi Hu, Yan Chen, Kecheng Xu, Yangzhe Wu, Zhinan Yin
BACKGROUND: Cholangiocarcinoma (CCA) is a highly aggressive and fatal tumor. CCA occurs in the epithelial cells of bile ducts. Due to increasing incidences, CCA accounts for 3% of all gastrointestinal malignancies. In addition to comprehensive treatments for cancer, such as surgery, chemotherapy, and radiotherapy, during the past few years, cellular immunotherapy has played an increasingly important role. As a result of our research, we have discovered the γδ T cell-based immunotherapy for CCA...
February 8, 2019: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/30723701/a-multicenter-phase-ii-trial-of-docetaxel-cisplatin-and-cetuximab-tpex-followed-by-cetuximab-and-concurrent-radiotherapy-for-patients-with-local-advanced-squamous-cell-carcinoma-of-the-head-and-neck-cspor-hn01-ecrips-study
#5
Sadamoto Zenda, Yosuke Ota, Naomi Kiyota, Susumu Okano, Masato Fujii, Morimasa Kitamura, Shunji Takahashi, Tsutomu Ueda, Nobuya Monden, Takeharu Yamanaka, Makoto Tahara
Background: Induction chemotherapy (IC) is a treatment option for locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). However, treatment with docetaxel, cisplatin, and 5-FU (TPF) followed by cisplatin and radiotherapy is controversial because of toxicity concerns. The aim of this phase II study was to assess the feasibility of docetaxel, cisplatin, and cetuximab (TPEx) followed by cetuximab and concurrent radiotherapy for LA SCCHN. Patients and Methods: We enrolled patients with histological evidence of squamous cell carcinoma of the oropharynx, hypopharynx, or larynx without distant metastases...
2019: Frontiers in Oncology
https://read.qxmd.com/read/30718072/ramucirumab-with-cisplatin-and-fluoropyrimidine-as-first-line-therapy-in-patients-with-metastatic-gastric-or-junctional-adenocarcinoma-rainfall-a-double-blind-randomised-placebo-controlled-phase-3-trial
#6
Charles S Fuchs, Kohei Shitara, Maria Di Bartolomeo, Sara Lonardi, Salah-Eddin Al-Batran, Eric Van Cutsem, David H Ilson, Maria Alsina, Ian Chau, Jill Lacy, Michel Ducreux, Guillermo Ariel Mendez, Alejandro Molina Alavez, Daisuke Takahari, Wasat Mansoor, Peter C Enzinger, Vera Gorbounova, Zev A Wainberg, Susanna Hegewisch-Becker, David Ferry, Ji Lin, Roberto Carlesi, Mayukh Das, Manish A Shah
BACKGROUND: VEGF and VEGF receptor 2 (VEGFR-2)-mediated signalling and angiogenesis can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess whether the addition of ramucirumab, a VEGFR-2 antagonist monoclonal antibody, to first-line chemotherapy improves outcomes in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. METHODS: For this double-blind, randomised, placebo-controlled, phase 3 trial done at 126 centres in 20 countries, we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate organ function...
February 1, 2019: Lancet Oncology
https://read.qxmd.com/read/30717797/avelumab-anti-pd-l1-as-first-line-switch-maintenance-or-second-line-therapy-in-patients-with-advanced-gastric-or-gastroesophageal-junction-cancer-phase-1b-results-from-the-javelin-solid-tumor-trial
#7
Hyun Cheol Chung, Hendrik-Tobias Arkenau, Jeeyun Lee, Sun Young Rha, Do-Youn Oh, Lucjan Wyrwicz, Yoon-Koo Kang, Keun-Wook Lee, Jeffrey R Infante, Sung Sook Lee, Margaret Kemeny, Ulrich Keilholz, Bohuslav Melichar, Alain Mita, Ruth Plummer, Denis Smith, Arnold B Gelb, Huiling Xiong, Janet Hong, Vikram Chand, Howard Safran
BACKGROUND: We evaluated the antitumor activity and safety of avelumab, a human anti-PD-L1 IgG1 antibody, as first-line switch-maintenance (1 L-mn) or second-line (2 L) treatment in patients with advanced gastric/gastroesophageal cancer (GC/GEJC) previously treated with chemotherapy. METHODS: In a phase 1b expansion cohort, patients without (1 L-mn) or with (2 L) disease progression following first-line chemotherapy for advanced GC/GEJC received avelumab 10 mg/kg intravenously every 2 weeks...
February 4, 2019: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/30713783/retrospective-analysis-of-the-efficacy-of-adjuvant-cik-cell-therapy-in-epithelial-ovarian-cancer-patients-who-received-postoperative-chemotherapy
#8
Yun Zhou, Chang-Long Chen, Sen-Wei Jiang, Yanling Feng, Linjing Yuan, Ping Chen, Lan Zhang, Shuting Huang, Jundong Li, Jian-Chuan Xia, Min Zheng
Cytokine-induced killer (CIK) cells are demonstrated to possess potent cytolytic effect against ovarian cancer cells in vitro and in vivo . However, the clinical efficacy of maintenance therapy of CIK cells in patients with epithelial ovarian cancer (EOC) after first-line treatment remains unclear. This retrospective study included 646 cases of postoperative EOC patients, 72 of which received chemotherapy and sequential immunotherapy (CIT group), and 574 of which received only chemotherapy (Control group). Patients in the CIT group received at least four cycles of CIK cell (range 8...
2019: Oncoimmunology
https://read.qxmd.com/read/30711967/the-effect-of-supplementary-omegaven%C3%A2-on-the-clinical-outcome-of-patients-with-advanced-esophagogastric-adenocarcinoma-receiving-palliative-epirubicin-oxaliplatin-and-capecitabine-chemotherapy-a-phase-ii-clinical-trial
#9
Amar M Eltweri, Anne L Thomas, Wen Y Chung, Bruno Morgan, John Thompson, Ashley R Dennison, David J Bowrey
BACKGROUND/AIM: Previous studies have shown anti-proliferative and anti-apoptotic effects of omega-3 fatty acids (Omegaven®) in vitro and in vivo. Whether this effect can be exploited in patients with advanced esophago-gastric adenocarcinoma is unknown. The present study intended to determine the tumour radiological response and toxicity profile of intravenous omega-3 fish oil infusion when combined with standard palliative chemotherapy, and present the effects of this treatment on plasma cytokine biomarkers...
February 2019: Anticancer Research
https://read.qxmd.com/read/30711662/brain-and-bone-cancer-targeting-by-a-ferrofluid-composed-of-superparamagnetic-iron-oxide-silica-carbon-nanoparticles-earthicles
#10
Victoria M Wu, Eric Huynh, Sean Tang, Vuk Uskoković
Despite the advances in molecularly targeted therapies, delivery across the blood-brain barrier (BBB) and the targeting of brain tumors remains a challenge. To tackle it, we made a variation on the previously proposed concept of the earthicle and fabricated an aqueous, surfactant-free ferrofluid containing superparamagnetic iron oxide nanoparticles (SPIONs) coated with silicate mesolayers and carbon shells, having 13 nm in size on average. Nanoparticles were synthesized hydrothermally and characterized using a range of spectroscopic, diffractometric, hydrodynamic and electron microscopy techniques...
January 31, 2019: Acta Biomaterialia
https://read.qxmd.com/read/30709431/tolerability-and-activity-of-ublituximab-umbralisib-and-ibrutinib-in-patients-with-chronic-lymphocytic-leukaemia-and-non-hodgkin-lymphoma-a-phase-1-dose-escalation-and-expansion-trial
#11
Loretta J Nastoupil, Matthew A Lunning, Julie M Vose, Marshall T Schreeder, Tanya Siddiqi, Christopher R Flowers, Jonathon B Cohen, Jan A Burger, William G Wierda, Susan O'Brien, Peter Sportelli, Hari P Miskin, Michelle A Purdom, Michael S Weiss, Nathan H Fowler
BACKGROUND: Therapeutic approaches for B-cell malignancies continue to evolve, especially with regard to combination approaches. We assessed the safety and efficacy of the triplet ublituximab, umbralisib, and ibrutinib in patients with advanced B-cell malignancies. METHODS: We did an open-label, phase 1 study with dose-escalation and dose-expansion phases, at five centres in the USA. Eligible patients were aged 18 years or older with histologically confirmed lymphocytic leukaemia or relapsed or refractory B-cell non-Hodgkin lymphoma, had measurable disease, adequate organ function, and an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less...
February 2019: Lancet Haematology
https://read.qxmd.com/read/30707660/gemcitabine-and-oxaliplatin-chemotherapy-or-surveillance-in-resected-biliary-tract-cancer-prodige-12-accord-18-unicancer-gi-a-randomized-phase-iii-study
#12
Julien Edeline, Meher Benabdelghani, Aurélie Bertaut, Jérôme Watelet, Pascal Hammel, Jean-Paul Joly, Karim Boudjema, Laetitia Fartoux, Karine Bouhier-Leporrier, Jean-Louis Jouve, Roger Faroux, Véronique Guerin-Meyer, Jean-Emmanuel Kurtz, Eric Assénat, Jean-François Seitz, Isabelle Baumgaertner, David Tougeron, Christelle de la Fouchardière, Catherine Lombard-Bohas, Eveline Boucher, Trevor Stanbury, Christophe Louvet, David Malka, Jean-Marc Phelip
PURPOSE: No standard adjuvant treatment currently is recommended in localized biliary tract cancer (BTC) after surgical resection. We aimed to assess whether gemcitabine and oxaliplatin chemotherapy (GEMOX) would increase relapse-free survival (RFS) while maintaining health-related quality of life (HRQOL) in patients who undergo resection. PATIENTS AND METHODS: We performed a multicenter, open-label, randomized phase III trial in 33 centers. Patients were randomly assigned (1:1) within 3 months after R0 or R1 resection of a localized BTC to receive either GEMOX (gemcitabine 1,000 mg/m2 on day 1 and oxaliplatin 85 mg/m2 infused on day 2 of a 2-week cycle) for 12 cycles (experimental arm A) or surveillance (standard arm B)...
February 1, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/30706408/safety-profile-of-htx-019-administered-as-an-intravenous-push-in-cancer-patients-a-retrospective-review
#13
Gary D Walton
INTRODUCTION: HTX-019 [CINVANTI® (aprepitant injectable emulsion)] is a neurokinin 1 receptor antagonist (NK-1 RA) approved as a 30-min infusion for preventing acute and delayed chemotherapy-induced nausea and vomiting. HTX-019 has been generally well tolerated when administered as a 30-min infusion or 2-min injection [intravenous (IV) push] in healthy subjects. This real-world analysis assesses safety of HTX-019 via IV push in patients with cancer and addresses a recent IV bag shortage...
January 31, 2019: Advances in Therapy
https://read.qxmd.com/read/30704923/eltrombopag-treatment-during-induction-chemotherapy-for-acute-myeloid-leukaemia-a-randomised-double-blind-phase-2-study
#14
Noelle Frey, Jun Ho Jang, Jeff Szer, Árpád Illés, Hee-Je Kim, Ron Ram, Beng H Chong, Jacob M Rowe, Elena Borisenkova, Jane Liesveld, Eric S Winer, Azzeddine Cherfi, Vassilios Aslanis, Farhat Ghaznawi, Stephen Strickland
BACKGROUND: Patients with acute myeloid leukaemia frequently have thrombocytopenia during induction chemotherapy. Eltrombopag, an oral thrombopoietin receptor agonist, stimulates platelet production by a similar mechanism to endogenous thrombopoietin. This study investigated safety and efficacy of eltrombopag versus placebo during anthracycline-based induction treatment of patients with acute myeloid leukaemia. METHODS: In this randomised, double-blind, phase 2 study, treatment-naive patients were recruited from clinical centres across 10 countries (Australia, Belgium, Canada, Greece, Hungary, Israel, South Korea, Poland, Russia, and the USA)...
January 28, 2019: Lancet Haematology
https://read.qxmd.com/read/30702598/intraperitoneal-infusion-of-ex-vivo-cultured-allogeneic-nk-cells-in-recurrent-ovarian-carcinoma-patients-a-phase-i-study
#15
Janneke Hoogstad-van Evert, Ruud Bekkers, Nelleke Ottevanger, Nicolaas Schaap, Willemijn Hobo, Joop H Jansen, Leon Massuger, Harry Dolstra
INTRODUCTION: Recurrent ovarian carcinoma has dismal prognosis, but control of disease and prolonged survival are possible in some patients. The estimated 5-year survival is 46% for all stages of ovarian cancer, and only 28% for metastasized disease. Notably, the majority of women with ovarian cancer are diagnosed with stage III or IV disease with a high recurrence rate. As most women with relapsed or metastatic cancer will die of progressive disease, there is an urgent need for novel therapeutic strategies...
February 2019: Medicine (Baltimore)
https://read.qxmd.com/read/30701030/neoadjuvant-intra-arterial-chemotherapy-using-an-original-four-lumen-double-balloon-catheter-for-locally-advanced-uterine-cervical-cancer
#16
Tomohito Tanaka, Yoshito Terai, Satoe Fujiwara, Yoshimichi Tanaka, Hiroshi Sasaki, Satoshi Tsunetoh, Kazuhiro Yamamoto, Takashi Yamada, Masahide Ohmichi
OBJECTIVE: We report a balloon-occluded arterial infusion therapy with an original four-lumen double-balloon catheter (4L-DB) which allows for the efficient injection of an anticancer agent at a high concentration to the target spot for patients with locally advanced uterine cervical cancer. METHODS: One hundred and forty-three patients with locally advanced cervical cancer treated with neoadjuvant intra-arterial chemotherapy (NAIAC) or a primary radical hysterectomy (PRH) were retrospectively assessed...
December 28, 2018: Oncotarget
https://read.qxmd.com/read/30700474/capeox-perioperative-chemotherapy-versus-postoperative-chemotherapy-for-locally-advanced-resectable-colon-cancer-protocol-for-a-two-period-randomised-controlled-phase-iii-trial
#17
Fangqi Liu, Tong Tong, Dan Huang, Weitang Yuan, Dechuan Li, Jianjiang Lin, Sanjun Cai, Ye Xu, Wenbin Chen, Yueming Sun, Jing Zhuang
INTRODUCTION: Adjuvant chemotherapy with the CapeOX regimen is now widely used for treating colorectal cancer. However, prior studies have demonstrated better efficacy of pre-operative/neoadjuvant chemotherapy without increase of safety risks. METHODS AND ANALYSIS: This multicentre, open-label, parallel-group, randomised, controlled, phase III study aims to compare the efficacy and safety of perioperative CapeOX chemotherapy with the postoperative one for treating patients with locally advanced R0 resectable colon cancers in China...
January 29, 2019: BMJ Open
https://read.qxmd.com/read/30697816/incidence-and-risk-factors-associated-with-development-of-clinical-cardiotoxicity-in-dogs-receiving-doxorubicin
#18
Briana E Hallman, Marlene L Hauck, Laurel E Williams, Paul R Hess, Steven E Suter
BACKGROUND: Doxorubicin (DOX) can cause cumulative cardiotoxicity in dogs, but the incidence of clinical cardiotoxicity in dogs receiving DOX has not been determined. HYPOTHESIS/OBJECTIVES: To determine if the duration of DOX infusion influences the incidence of cardiotoxicity, to characterize the incidence of clinical cardiotoxicity in dogs during or after DOX chemotherapy, and to identify any risk factors associated with cardiotoxicity. ANIMALS: Four-hundred ninety-four dogs that received at least 1 dose of DOX for the treatment of cancer...
January 29, 2019: Journal of Veterinary Internal Medicine
https://read.qxmd.com/read/30694002/prognostic-factors-and-treatment-outcomes-of-advanced-maxillary-gingival-squamous-cell-carcinoma-treated-by-intra-arterial-infusion-chemotherapy-concurrent-with-radiotherapy
#19
Yuichiro Hayashi, Kohei Osawa, Rina Nakakaji, Shuhei Minamiyama, Nobuhide Ohashi, Takashi Ohya, Masaki Iida, Toshinori Iwai, Tomomichi Ozawa, Senri Oguri, Toshiyuki Koizumi, Makoto Hirota, Mitomu Kioi, Masaharu Hata, Kenji Mitsudo
BACKGROUND: The aim of this study was to evaluate the prognostic factors and treatment outcomes of advanced maxillary gingival squamous cell carcinoma (SCC) treated with intra-arterial infusion chemotherapy concurrent with radiotherapy. METHODS: A total of 46 patients were reviewed retrospectively in this study. The treatment schedule comprised intra-arterial chemotherapy (total, 60 mg/m2 docetaxel and 150 mg/m2 cisplatin) and three-dimensional computed tomography based, daily conventional radiotherapy (total, 60 Gy/30 fr) for 6 weeks...
January 29, 2019: Head & Neck
https://read.qxmd.com/read/30693935/a-responsive-porous-hydrogel-particle-based-delivery-system-for-oncotherapy
#20
Yuanyuan Wen, Yuxiao Liu, Han Zhang, Minhan Zou, Dan Yan, Dingding Chen, Yuanjin Zhao
Liver cancer is one of the malignant cancers that seriously threatens human health. Although some common treatments including chemotherapy have been applied in oncotherapy, there are often serious shortcomings such as frequent and uncontrollable drug infusion. To overcome these limitations, here, we introduced responsive porous hydrogel microparticles loaded with 5-fluorouracil and metformin for oncotherapy. Because of the interconnected porous structures, various forms of active molecules could be loaded into the particles...
January 29, 2019: Nanoscale
keyword
keyword
164990
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"